The recent advance of direct anti-HBV drug candidates in clinical trials
10.16438/j.0513-4870.2022-0318
- VernacularTitle:直接抗乙肝病毒候选药物的临床试验研究进展
- Author:
Mei WANG
1
;
Lin-yue LIU
1
;
Chuan-ju LI
1
;
Jun LIU
2
;
Hai-yong JIA
1
Author Information
1. School of Pharmacy, Weifang Medical University, Weifang 261053, China
2. School of Nursing, Weifang Medical University, Weifang 261053, China
- Publication Type:Research Article
- Keywords:
hepatitis B virus;
rug target;
nucloes(t)ide analogue;
irect antiviral agent
- From:
Acta Pharmaceutica Sinica
2022;57(10):2972-2984
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a serious global public health problem. Chronic hepatitis B virus infection can cause health problems such as cirrhosis, liver metabolism disorders and hepatocellular carcinoma. Nucloes(t)ide analogues and interferon drugs used to treat chronic HBV infection do not completely eradicate covalently closed circular DNA (cccDNA) and integrated genome of HBV DNA, so that they cannot achieve the functional cure of chronic HBV infection. Currently, a series of drugs targeting the phases of HBV lifecycle and immunomodulators have entered clinical trials. Here, we review the current status of the therapeutic drugs as well as the recent advance of direct antiviral agents.
